[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT07718347":3,"trial-entities:NCT07718347":134,"trial-summary:NCT07718347":139},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":22,"study_type":27,"primary_purpose":28,"phases":29,"enrollment_info":31,"interventions":34,"primary_outcomes":42,"secondary_outcomes":66,"sex":67,"minimum_age":68,"maximum_age":69,"healthy_volunteers":70,"eligibility_criteria":71,"std_ages":88,"locations":91,"central_contacts":120,"overall_officials":125,"references":126,"see_also_links":133},"NCT07718347","LRM-ARS-PLF 401","Post-market Cosmetic Evaluation of Ariessence™ Pure PDGF+ Following Ablative Laser","A Multi-center, Post-market Cosmetic Evaluation of Ariessence™ Pure PDGF+ Following Ablative Laser for the Tolerability and Improvement in the Appearance of Aging Skin.","RECRUITING","2027-02","2026-07","2026-07-21","2026-04-16","Lynch Regenerative Medicine","NETWORK",true,"ariessence is intended to be used as a viscous, leave-on solution designed for topical application to the face. It is intended to be used following non-medical cosmetic procedures, performed by licensed healthcare professionals to enhance comfort and maintain skin hydration. This study is designed to be a multi-center, post-market cosmetic evaluation of ariessence applied to the full face after an ablative laser procedure to evaluate improvements in procedure tolerability and improvements in the appearance of the skin, compared to an emollient control.","To compare procedure tolerability of the treated facial area between ariessence and standard aftercare (Aquaphor). Tolerability, using subject tolerability assessments (subject diaries), investigator tolerability assessments, and standardized day-3\u002F7\u002F14 photographs, with site confirmation.",[19,20,21],"Immediate Post-Treatment Care","Aging Mid-Face","Aging",[23,24,25,26],"PDGF","aging skin","post-laser treatment","ariessence","INTERVENTIONAL","TREATMENT",[30],"NA",{"count":32,"type":33},21,"ESTIMATED",[35],{"type":36,"name":37,"description":38,"armGroupLabels":39},"OTHER","ariessence pure PDGF+™ is a sterile aqueous formulation containing Hyaluronic Acid and pure platelet-derived growth factor (PDGF).","To compare time to appearance-based recovery and subject satisfaction between ariessence and standard of care groups using standardized photographs and investigator\u002Fsubject ratings for tolerability and satisfaction",[40,41],"ariessence pure PDGF+","standard of care",[43,47,51,55,58,62],{"measure":44,"description":45,"timeFrame":46},"Clinical Measures","Glogau Scale","Baseline (Day 0) through Day 84 (End of Study).",{"measure":48,"description":49,"timeFrame":50},"Patient-Reported Outcomes","FACE-Q, SKIN-Q, FACE-Q Psychological Function, treatment Discomfort\u002FPain Evaluation Subject Satisfaction Scale","Baseline through day 84",{"measure":52,"description":53,"timeFrame":54},"Photography","VISIA-CR (standardized frontal ±45°), FitSkin (regional close-ups), and point-and-shoot baseline and follow-ups","Baseline through Day 84",{"measure":56,"description":57,"timeFrame":54},"Investigator Objective Tolerability Assessment","Tolerability of product",{"measure":59,"description":60,"timeFrame":61},"Erythema grading (0-4 scale)","Degree of erthema","Baseline through Day 84 (End of Study)",{"measure":63,"description":64,"timeFrame":65},"Clinician's Global Aesthetic Improvement Scale (CGAIS).","Measure of Aestetic Imporvement","Baseline through Day 84 (End of STudy)",[],"ALL","40 Years","70 Years",false,{"inclusion":72,"exclusion":80,"raw_text":87},[73,74,75,76,77,78,79],":Adults 40-65 70 years","Glogau III-IV","Fitzpatrick II-IV.","Suitable for ablative laser","non-smoker ≥ 3 years","Willing to comply with post-procedure regimen","patient reported outcome documentation, and photo documentation.",[81,82,83,84,85,86],"Fitzpatrick I or \\> IV,","recent facial procedures (\\\u003C 6 months)","active skin disease","pregnancy\u002Flactation","implanted devices","history of keloids.","Inclusion Criteria\n\n-:Adults 40-65 70 years\n\n* Glogau III-IV\n* Fitzpatrick II-IV.\n* Suitable for ablative laser\n* non-smoker ≥ 3 years\n* Willing to comply with post-procedure regimen\n* patient reported outcome documentation, and photo documentation.\n\nExclusion Criteria:\n\n* Fitzpatrick I or \\> IV,\n* recent facial procedures (\\\u003C 6 months)\n* active skin disease\n* pregnancy\u002Flactation\n* implanted devices\n* history of keloids.",[89,90],"ADULT","OLDER_ADULT",[92,108],{"facility":93,"status":8,"city":94,"state":95,"zip":96,"country":97,"contacts":98,"geoPoint":105},"Laser & Skin Surgery Medical Group","Sacramento","California","95816","United States",[99],{"name":100,"role":101,"phone":102,"phoneExt":103,"email":104},"Suzanne Kilmer, MD","CONTACT","916-456-0400","216","Nathan.Smith@purity-health.com",{"lat":106,"lon":107},38.58157,-121.4944,{"facility":109,"status":8,"city":110,"state":111,"zip":112,"country":97,"contacts":113,"geoPoint":117},"The Practice of Brian S. Biesman, MD","Nashville","Tennessee","37203",[114],{"name":115,"role":101,"phone":116,"email":104},"Brian S Biesman, MD","615-329-1110",{"lat":118,"lon":119},36.16589,-86.78444,[121],{"name":122,"role":101,"phone":123,"email":124},"Josh Arnold","302-604-4532","clinicaltrials@purity-health.com",[],[127,130],{"type":128,"citation":129},"BACKGROUND","Sharma AN, Patel BC. Laser Fitzpatrick Skin Type Recommendations. In: StatPearls. StatPearls Publishing; 2025. Accessed October 28, 2025. http:\u002F\u002Fwww.ncbi.nlm.nih.gov\u002Fbooks\u002FNBK557626\u002F",{"pmid":131,"type":128,"citation":132},"8948530","Glogau RG. Aesthetic and anatomic analysis of the aging skin. Semin Cutan Med Surg. 1996 Sep;15(3):134-8. doi: 10.1016\u002Fs1085-5629(96)80003-4.",[],{"nct_id":4,"conditions":135,"biomarkers":138},[20,136,137],"Hanging skin","Post-Laser Treatment",[],{"nct_id":4,"found":15,"summary":140,"prompt_version":150},{"design":141,"status":142,"heading":143,"summary":144,"follow_up":145,"word_count":146,"commitments":147,"compensation":148,"drugs_mentioned":149},"This interventional study plans to enroll 21 participants to compare ariessence pure PDGF+™ to standard care after ablative laser treatment.","completed","Cosmetic Evaluation of Ariessence™ Pure PDGF+ After Laser Treatment","This study is evaluating a product called ariessence pure PDGF+™ (which contains Hyaluronic Acid and platelet-derived growth factor, or PDGF) for use after ablative laser procedures. Researchers want to see if ariessence helps with recovery and improves skin appearance compared to standard aftercare (Aquaphor). You might be able to join if you are between 40 and 70 years old, have specific skin types (Glogau III-IV and Fitzpatrick II-IV), are suitable for ablative laser, and are a non-smoker. The study will measure how well you tolerate the procedure, your satisfaction, and changes in your skin's appearance using photos and ratings. The current recruitment status is unclear.","Participants will be followed for 84 days after the start of the study, with measurements taken at various points during this time.",105,"You would need to comply with a post-procedure regimen, document your outcomes, and have photos taken from the start of the study through Day 84.","Not stated in the trial record.",[],"v2"]